ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
22 April 2015 - 9:35PM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
issuance of its first U.S. patent on brigatinib, ARIAD’s
investigational ALK inhibitor. The United States Patent and
Trademark Office granted U.S. Patent No. 9,012,462 under the title,
“Phosphorous Derivatives as Kinase Inhibitors.” The patent provides
composition-of-matter protection through at least December 30, 2030
for ARIAD’s investigational ALK inhibitor, brigatinib. Additional
patent applications covering brigatinib are pending in the U.S. and
in other countries.
“This has been an important week for brigatinib, beginning with
ARIAD’s presentation of preclinical and clinical data on brigatinib
and the unveiling of its novel design features at the American
Association for Cancer Research (AACR) Annual Meeting. The issuance
of the initial brigatinib patent highlights the innovative design
of the brigatinib molecule,” stated Harvey J. Berger, M.D.,
chairman and chief executive officer of ARIAD. “We continue to
enroll patients in our Phase 2 ALTA trial and look forward to
sharing the first data from that clinical trial later this
year.”
About Brigatinib
Brigatinib (AP26113) is an investigational, targeted cancer
medicine discovered internally at ARIAD Pharmaceuticals, Inc. It is
in development for the treatment of patients with anaplastic
lymphoma kinase positive (ALK+) metastatic non-small cell lung
cancer (NSCLC) that is resistant to crizotinib. Brigatinib received
Breakthrough Therapy designation from the FDA in October 2014 for
the treatment of patients with ALK+ NSCLC that is resistant to
crizotinib on the basis of an ongoing Phase 1/2 trial. Brigatinib
is currently being evaluated in the global Phase 2 ALTA trial that
is anticipated to form the basis for its initial regulatory
review.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit http://www.ariad.com
or follow ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking
statements. Any statements contained herein which do not describe
historical facts, including, but not limited to, statements
regarding: the duration of the U.S. composition of matter patent
for brigatinib and the status of additional patent applications
covering brigatinib; the expected timing for disclosing data from
our ongoing Phase 2 ALTA clinical trial of brigatinib; and our
ongoing Phase 1/2 trial of brigatinib in patients with ALK+ NSCLC,
are forward-looking statements which are based on management's
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events,
timing and performance to differ materially from those expressed or
implied by such statements. These factors, risks and uncertainties
include, among others: our ability to maintain and enforce patent
protection for our product candidates, including the risk of patent
challenges by third parties; preclinical data and early-stage
clinical data may not be replicated in later-stage clinical
studies; the costs associated with our research, development,
manufacturing and other activities; the adequacy of our capital
resources and the availability of additional funding; our ongoing
and additional clinical trials of brigatinib may not be successful
or initiated, enrolled or conducted in a timely manner; regulatory
developments and safety issues; competitive risks; manufacturing
issues and those additional factors detailed in our public filings
with the U.S. Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. All forward‐looking statements in this press release are
qualified in their entirety by this cautionary statement.
ARIAD Pharmaceuticals, Inc.For InvestorsKendra Adams,
617-503-7028kendra.adams@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2024 to May 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From May 2023 to May 2024